---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Arimoclomol"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Arimoclomol. Topics: Guideline recommendation: arimoclomol for patients with neurological symptoms on background miglustat, U.S. regulatory history: complete response letter in June 2021, U.S. regulatory history: advisory committee vote in August 2024, U.S. approval in September 2024 in combination with miglustat, and 9 further topics. 13 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/arimoclomol"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Arimoclomol

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Arimoclomol

<a id="topic-2.2.2.1.3-1"></a>

### Guideline recommendation: arimoclomol for patients with neurological symptoms on background miglustat

> “Arimoclomol is a small‐molecule drug classified as a heat shock protein co‐inducer, targeting HSP70, approved by the FDA in combination with miglustat for the treatment of NPC”
> “Statement #17: All patients with a confirmed diagnosis of NPC and neurological symptoms using background miglustat treatment should be considered for arimoclomol therapy.”
> “Expert's opinion: completely agree (37.93%), mostly agree (37.93%), partially agree (20.69%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.3-2"></a>

### U.S. regulatory history: complete response letter in June 2021

> “Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC).”
> “The FDA issued the CRL based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation of the 5-domain NPC Clinical Severity Scale (NPCCSS) and, in particular, the swallow domain.”
> “Further, the FDA noted in the CRL that additional data are needed to bolster confirmatory evidence beyond the single phase 2/3 clinical trial to support the benefit-risk assessment of the NDA.”

Source: [Orphazyme complete response letter announcement (2021)](https://www.sec.gov/Archives/edgar/data/1764791/000156459021033445/orph-ex991_6.htm)

<a id="topic-2.2.2.1.3-3"></a>

### U.S. regulatory history: advisory committee vote in August 2024

> “CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C (NPC).”
> “The FDA has accepted the resubmission of the NDA for arimoclomol and has set a user fee goal action date (PDUFA date) of September 21, 2024.”

Source: [Zevra Therapeutics advisory committee release (2024)](https://www.biospace.com/fda-advisory-committee-votes-favorably-that-the-data-support-arimoclomol-as-effective-treatment-for-patients-with-niemann-pick-disease-type-c)

<a id="topic-2.2.2.1.3-4"></a>

### U.S. approval in September 2024 in combination with miglustat

> “Today, the U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).”
> “Miplyffa, in combination with the enzyme inhibitor miglustat, is approved to treat neurological symptoms associated with NPC in adults and children 2 years of age and older.”
> “Miplyffa is the first drug approved by the FDA to treat NPC.”
> “The FDA granted Miplyffa priority review, orphan drug, rare pediatric disease, fast track and breakthrough therapy designations for this application.”

Source: [FDA Miplyffa approval announcement (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c)

> “MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC).”
> “Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes.”

Source: [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm)

<a id="topic-2.2.2.1.3-5"></a>

### Phase 2/3 trial NPC-002: prespecified 5-domain NPCCSS primary endpoint

> “In a 12‐month, prospective, randomised, double‐blind, placebo‐controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2‐18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use.”
> “The primary endpoint was change in 5‐domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months.”
> “Fifty patients enrolled; 42 completed.”
> “At month 12, the mean progression from baseline in the 5‐domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo.”
> “A statistically significant treatment difference in favour of arimoclomol of −1.40 (95% confidence interval: −2.76, −0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression.”
> “In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of −2.06 in favour of arimoclomol (P = .006).”
> “Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo.”
> “Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%).”
> “Treatment‐related serious adverse events (n = 2) included urticaria and angioedema.”

Source: [Mengel et al. (2021a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9293014/)

<a id="topic-2.2.2.1.3-6"></a>

### Phase 2/3 trial NPC-002: rescored 4-domain NPCCSS introduced post hoc

> “To more accurately assess changes in disease course over a 12-month time period in a heterogeneous group of patients, the Cognition domain was removed from the 5DNPCCSS and the Swallow domain was rescored to reflect linearity in disease progression.”
> “The NPC-002 post-hoc primary analysis showed a mean standard error (SE) change in R4DNPCCSS score of 0.35 (0.40) with arimoclomol (N = 34) versus 2.05 (0.54) with placebo (N = 16), and a treatment effect in favor of arimoclomol over placebo of −1.70 (p = 0.0155).”
> “In the miglustat subgroup analysis, mean (SE) change in R4DNPCCSS score was −0.23 (1.02) with arimoclomol (N = 22) versus 1.92 (3.37) with placebo (N = 12), representing a treatment effect of −2.21 (p = 0.0077).”

Source: [Mengel et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12166820/)

<a id="topic-2.2.2.1.3-7"></a>

### Phase 2/3 trial NPC-002: results in the miglustat subgroup in the prescribing information

> “Safety and effectiveness of MIPLYFFA were assessed in Trial 1, a randomized, double-blind, placebo-controlled, 12-month trial in patients 2 to 19 years of age who had a molecularly confirmed diagnosis of NPC (NCT02612129).”
> “The randomization was stratified by miglustat use status at baseline.”
> “In Trial 1, 76% and 81% of patients in the MIPLYFFA and placebo groups, respectively, received miglustat six months or longer prior to the time of enrollment.”
> “Table 3 displays the change from baseline in R4DNPCCSS score at month 12 in patients 2 to 19 years of age with NPC who also received miglustat in Trial 1.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

| R4DNPCCSS score | MIPLYFFA with miglustat (N=26 at baseline, N=22 at month 12) | Placebo with miglustat (N=13 at baseline, N=12 at month 12) |
| --- | --- | --- |
| Baseline, mean (SD) | “8.9 (6.1)” | “7 (5.8)” |
| Change from baseline to month 12, mean (SD) | “-0.2 (1)” | “1.9 (3.4)” |
| Change from baseline to month 12, LS mean (SE) | “-0.2 (0.5)” | “2 (0.7)” |
| Placebo-subtracted difference (95% CI) | “-2.2 (-3.8, -0.6)” | Not applicable |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

> “Among these 50 patients, 39 (78%) received miglustat as background treatment in the trial.”
> “Miplyffa’s efficacy was demonstrated by the rescored 4-domain NPC Clinical Severity Scale (R4DNPCCSS) score in the patients who used miglustat as their background treatment.”
> “Compared to placebo, Miplyffa resulted in a slower disease progression as measured by the R4DNPCCSS score.”

Source: [FDA Miplyffa approval announcement (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c)

<a id="topic-2.2.2.1.3-8"></a>

### Appraisal of the phase 2/3 trial in a state Medicaid drug evaluation

> “There is low-certainty evidence from one 12-month, double-blind, phase II/III, randomized controlled trial (RCT) of patients age 2 to 19 years (n=50) that, when combined treatment with miglustat, arimoclomol improves symptoms of NPC compared to placebo combined with miglustat.”
> “The FDA determined the subgroup without miglustat had insufficient evidence to support use of arimoclomol monotherapy for NPC.”
> “This trial had methodological concerns with the endpoint which underwent alteration by the FDA as well as concerns with the standardization of procedures across trial sites which may reduce reliability of the results.”
> “After 12 months, people taking arimoclomol with another medicine called miglustat had a small improvement in symptoms compared to people taking placebo with miglustat.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.3-9"></a>

### Long-term data: 48-month open-label extension of NPC-002

> “Of the 50 patients who started the DB phase, 41 entered the OLE phase, with 29 completing 48 months.”
> “During the OLE, mean (SD) 5DNPCCS and R4DNPCCSS scores increased by 3.2 (4.8) and 2.7 (4.2) over 48 months, respectively.”
> “Among patients switching from placebo to arimoclomol after the DB phase, mean annual change in 5DNPCCSS decreased from 2.0 (on placebo) to 0.1 in the first year of receiving arimoclomol and mean annual change in R4DNPCCSS decreased from 1.9 to 0.2, indicating slowing of disease progression.”
> “The score pattern in the subset of patients who received miglustat as part of their standard care regime in addition to arimoclomol (N = 33) was similar to that seen in the total population.”
> “Arimoclomol was well-tolerated over 48 months, with no new safety concerns identified.”

Source: [Mengel et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40663813/)

<a id="topic-2.2.2.1.3-10"></a>

### Long-term data: U.S. early access program over 4 years

> “Participants were enrolled at 14 US sites.”
> “Among 109 participants, 53 (48.6%) were adults (≥18 years) and 71 (65.1%) received miglustat alongside arimoclomol.”
> “Mean (SD) arimoclomol exposure was 820 (539) days.”
> “Of 248 reported AEs, 17 events in 13 participants (12.8%) were treatment related.”
> “5DNPCCSS scores remained relatively stable throughout the program, with mean (SD) total scores of 11.0 (6.15) at Baseline (n = 100) and 12.0 (7.32) at Year 4 (n = 22).”

Source: [Berry-Kravis et al. (2026d)](https://pubmed.ncbi.nlm.nih.gov/42551329/)

<a id="topic-2.2.2.1.3-11"></a>

### Infants younger than 24 months: open-label pediatric substudy

> “The dosing regimen used for patients <24 months differed from the regimen recommended in the FDA label.”
> “Five patients (three females, two males; aged 14–23 months at screening) were enrolled; four remained in the study >12 months; arimoclomol exposure ranged from 72 to 1109 days.”
> “All patients received concomitant miglustat.”
> “Two AEs in one patient (elevated alanine/aspartate aminotransferases) were considered probably related to arimoclomol and resolved within 51 days; the patient was withdrawn from the substudy.”
> “Further investigation in larger cohorts is warranted to elucidate the impact of arimoclomol in NPC patients under 2 years of age.”

Source: [Mengel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310637/)

<a id="topic-2.2.2.1.3-12"></a>

### Planned supplemental application for infants younger than 24 months

> “Following the publication of its pediatric data in Molecular Genetics and Metabolism Reports, Zevra met with the U.S. Food and Drug Administration (FDA) to discuss a potential supplemental New Drug Application (sNDA) for MIPLYFFA in infants less than 24 months of age.”
> “Company anticipates filing sNDA in Q1 2027.”

Source: [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm)

<a id="topic-2.2.2.1.3-13"></a>

### Regulatory status outside the United States: refusal of European Union marketing authorisation confirmed in November 2026

> “After re-examining its initial opinion, the European Medicines Agency has confirmed its recommendation to refuse marketing authorisation for the medicine Meplyffa.”
> “The Agency issued its opinion after re-examination on 12 November 2026.”
> “The Agency had issued its initial opinion on 23 July 2026.”
> “Note: A previous application for this medicine (under the name Miplyffa) was withdrawn in March 2022.”

Source: [European Medicines Agency Meplyffa refusal (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/meplyffa)

> “At the time of the initial evaluation, there were concerns about how the data had been handled and the results analysed, which led to uncertainties about the reliability and robustness of the results.”
> “Moreover, no benefit was seen in terms of ambulation and cognition.”
> “Although data for the subgroup of patients who were also taking miglustat showed a treatment effect favouring Meplyffa, this finding was not considered robust since effectiveness had not been demonstrated in the overall population.”
> “While recognising the unmet medical need in Niemann-Pick disease type C, the Agency considered that its concerns were not resolved after re-examination and therefore confirmed the initial refusal.”

Source: [European Medicines Agency Meplyffa refusal questions and answers (2026)](https://www.ema.europa.eu/en/documents/smop-initial/questions-answer-refusal-marketing-authorisation-meplyffa-arimoclomol_en.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
